Prime Medicine, Inc. wins arbitration vs. Beam Therapeutics Inc., advancing PM647 for AATD. Read more on PRME and BEAM stocks ...

InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV) The Company is assessing the most efficient ...

For decades, many runners, and even coaches, have assumed that being a runner meant never walking during a training run or race. Even the most accomplished runners would apologize when they walked at ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By James Austin James Austin is a writer covering games and hobbies, which means ...